NCT02549391View on ClinicalTrials.gov

Phase 3 Study of KHK7580

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

634

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

KHK7580

Oral administration

DRUG

KRN1493

Oral administration

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02549391 - Phase 3 Study of KHK7580 | Biotech Hunter | Biotech Hunter